Specify a stock or a cryptocurrency in the search bar to get a summary
Avenue Therapeutics Inc
ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
Analytics
WallStreet Target Price
12 USDP/E ratio
0.067Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ATXI
Dividend Analytics ATXI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATXI
Stock Valuation ATXI
Financials ATXI
Results | 2019 | Dynamics |